University of California

Jogeshwar Mukherjee

Aparna Baranwal

Neil Saigal

Ping Wang

George Chandy

Steven Potkin

Pooja C Patel

Nehal Mahendra Shah

Megan Rose Felix

Gurleen Samra

Balu Easwaramoorthy

Sharon A Kuruvilla

Harsh Saigal, Legal Representative

Crystal Wang

Ramaiah Pichika

Norah Milne

Kenneth Dang

Min-Liang Pan

Heather Ho

Joseph Mantil

Frances Leslie

Sankha Chattopadhyay

Adriana Garcia

Elizabeth Head

The disclosure provides for multi-targeting agents that assist in the targeted removal of amyloid beta plaques from the brain and surrounding vasculature of subjects with Alzheimer's disease, and methods of treatment thereof.

Multi-targeting agents for Alzheimer's disease therapy

The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes and related to monitor disease progression or treatment efficacy of candidate drugs.

Imaging agents for monitoring changes of dopamine receptors and methods of using thereof

Various compositions and methods for Quasi-Amadori products and derivatives thereof are contemplated in which a halogenated carbohydrate is reacted with a primary amino group of an affinity ligand. In especially preferred aspects, the Quasi-Amadori product is formed from 2-fluorodeoxyglucose and an affinity moiety that preferentially or selectively binds to a neural cell or neural structure. Where contemplated compounds includeF, PET imaging using compounds presented herein is especially preferred.

Compositions and methods for 18F-fluorodeoxyglycosylamines

Various compounds, compositions, and methods for binding to &#x3b2;-amyloid plaque and norepinephrine transporters are presented. Especially preferred compounds include those with a PET-detectable label.

&#x3b2;-amyloid plaque imaging agents

Contemplated compositions and methods are employed to bind in vitro and in vivo to an &#x3b1;4&#x3b2;2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with &#x3b1;4&#x3b2;2 dysfunction.

Labeled A4B2 ligands and methods therefor

Contemplated compositions and methods are employed to bind in vitro and in vivo to an &#x3b1;4&#x3b2;2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with &#x3b1;4&#x3b2;&#x3b2;2 dysfunction.

Labeled ALPHA4BETA2 ligands and methods therefor

Contemplated substituted arylpiperazinyl compounds, and most preferablyF-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently withF-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.

Compositions and methods related to serotonin 5-HT1A receptors

Compounds, compositions and methods are contemplated in which senile plaques and/or neurofibrillary tangles are labeled using compounds with improved permeability across the blood brain barrier and improved selective binding to senile plaques and/or neurofibrillary tangles. Contemplated compounds are derivatives of FDDNP or curcumin, which most preferably have improved solubility in aqueous solvents. Labeling is typically performed using a PET detectable label, and especiallyC andF.

&#x3b2;-amyloid and neurofibrillary tangle imaging agents

Growing community of inventors

Irvine, CA, United States of America

Jogeshwar Mukherjee